invas
fungal
infect
ifi
repres
signific
caus
morbid
mortal
patient
undergo
allogen
hematopoiet
stem
cell
transplant
cumul
incid
ifi
rang
vari
accord
sever
risk
factor
donor
type
durat
neutropenia
occurr
diseas
gvhd
requir
system
steroid
treatment
among
risk
factor
ifi
donor
type
variabl
potenti
use
dictat
choic
primari
antifung
prophylaxi
pap
prospect
studi
transnet
retrospect
analysi
gruppo
italiano
trapianto
midollo
osseo
gitmo
describ
incid
approxim
twice
high
mismatch
relat
donor
mmrd
compar
match
relat
donor
mrd
smaller
retrospect
studi
compris
differ
type
haploident
transplant
platform
consist
found
higher
risk
ifi
haploidenticalmmrd
transplant
rel
mrd
antifung
prophylaxi
heterogen
studi
rang
fluconazol
agent
report
support
urgent
need
stringent
pap
haploident
transplant
order
reduc
occurr
ifi
mortal
high
addit
epidemiolog
studi
fungal
infect
prophylaxi
last
year
shown
shift
candida
remain
second
major
caus
compris
albican
aspergillu
speci
frequent
agent
respons
ifi
given
background
recommend
employ
prophylaxi
patient
higher
risk
ifi
base
donor
type
haploident
cord
blood
time
transplant
phase
occurr
gvhd
itraconazol
voriconazol
posaconazol
receiv
level
recommend
last
version
ecil
data
avail
either
recommend
contraind
echinocandin
pap
base
unmet
need
pap
patient
state
novemb
employ
caspofungin
agent
consecut
patient
undergo
haploident
transplant
cyclophosphamid
institut
aim
studi
analyz
efficaci
caspofungin
pap
term
ifi
incid
first
day
term
patient
outcom
three
main
condit
regimen
employ
nma
regimen
compris
cy
mgkg
day
fludarabin
day
day
total
bodi
irradi
tbi
gy
day
b
reduc
intens
ric
regimen
compris
either
thiotepa
mgkg
day
cyclophosphamid
mgkg
day
day
fludarabin
day
day
thiotepa
mgkg
day
busulfan
mgkg
day
day
fludarabin
day
day
c
myeloabl
mac
condit
compris
thiotepa
mgkg
day
day
busulfan
mgkgdie
day
day
fludarabin
day
day
potenti
famili
member
type
loci
high
level
resolut
select
donor
also
type
locu
level
graft
sourc
repres
either
bone
marrow
bm
peripher
blood
stem
cell
pbsc
target
minimum
unmanipul
bm
peripher
blood
stem
cell
pbsc
use
stem
cell
support
day
graft
sourc
begin
mainli
repres
bone
marrow
baltimor
protocol
thereaft
pbsc
mainli
use
due
easier
collect
strategi
cyclophosphamid
mgkg
administ
day
day
transplant
cyclosporin
csa
dose
mgkg
continu
infus
discharg
convert
oral
formul
thereaft
csa
dosag
adjust
base
respect
rang
activ
ngml
mmf
administ
mgkg
po
three
time
per
day
day
csa
mmf
start
day
csa
taper
day
start
day
patient
neutrophil
engraft
defin
first
three
consecut
day
absolut
neutrophil
count
anc
transplant
platelet
engraft
defin
platelet
count
transfus
preced
day
acut
gvhd
agvhd
grade
accord
keyston
chronic
gvhd
cgvhd
retrospect
grade
follow
nih
patient
alloc
room
begin
condit
neutrophil
engraft
receiv
low
microbi
diet
blood
vessel
access
cvc
place
patient
underw
microbiolog
surveil
includ
cultur
stool
urin
swab
anal
area
start
condit
weekli
discharg
case
fever
defin
temperatur
follow
examin
perform
duplic
blood
cultur
thorax
ct
scan
bronchoalveolar
lavag
bal
possibl
case
type
lung
abnorm
suspici
infect
microbiolog
investig
includ
microscopi
cultur
direct
microscopi
sampl
examin
prepar
wet
mount
gram
stain
detect
presenc
yeast
cell
yeast
pseudohypha
septat
hypha
mold
sampl
fungal
cultur
inocul
sabouraud
dextros
agar
incub
yeast
identifi
maldi
tof
mold
identifi
use
lactophenol
cotton
blue
mount
slide
cultur
sampl
also
investig
cultur
presenc
staphylococcu
aureu
streptocooccu
pneumonia
pyogen
enterobacteriacea
haemophilu
influenza
moraxella
catharrali
galactomannan
threshold
posit
optic
densiti
pneumocisti
jroveci
immunohistochemistri
pcr
cmv
respiratori
viru
parainfluenza
influenza
b
adenoviru
respiratori
syncyti
viru
coronaviru
metapneumoviru
enteroviru
rhinoviru
bocaviru
antimicrobi
prophylaxi
begun
hospit
condit
regimen
consist
acyclovir
mg
per
day
levofloxacin
mg
per
day
sulfamethoxazol
trimethoprim
administ
tablet
per
day
day
resum
hematolog
reconstitut
dosag
tablet
everi
day
pap
consist
caspofungin
mgdie
day
follow
caspofungin
mgdie
day
neutrophil
engraft
histor
cohort
treat
itraconazol
receiv
iv
itraconazol
pap
dosag
mgdie
day
neutrophil
engraft
thereaft
pap
perform
mean
posaconazol
case
acut
gvhd
occurr
pcr
monitor
cytomegaloviru
perform
twice
per
week
day
day
routin
screen
ifi
perform
transplant
ifi
defin
accord
standard
intern
onset
defin
day
first
posit
radiolog
examin
posit
cultur
patholog
test
record
first
day
primari
endpoint
studi
investig
cumul
incid
ifi
infect
patient
receiv
pap
caspofungin
secondari
endpoint
outcom
paramet
overal
surviv
os
mortal
nrm
categor
variabl
express
proport
continu
variabl
median
respect
rang
cumul
incid
agvhd
estim
consid
death
relat
agvhd
within
year
compet
event
cgvhd
estim
patient
aliv
day
consid
death
relat
cgvhd
within
year
compet
calcul
nrm
diseas
relaps
progress
treat
compet
event
wherea
nrm
compet
event
calcul
cumul
incid
relaps
progress
method
use
os
surviv
pf
outcom
respect
confid
interv
ci
calcul
date
transplant
comparison
group
made
gray
test
whenev
indic
cumul
incid
day
estim
consid
death
reason
relat
ifi
infect
compet
event
univari
cox
regress
use
identifi
signific
moder
independ
covari
occurr
ifi
treat
explanatori
covari
account
effect
os
nrm
hazard
ratio
hr
confid
interv
ci
report
hr
denot
unfavor
effect
p
valu
consid
signific
spss
version
ibm
armonk
ny
usa
ezr
easi
r
r
institut
statist
comput
vienna
austria
use
first
day
cumul
incid
ci
case
figur
occur
patient
cumul
incid
ci
figur
among
case
common
diagnosi
lung
invas
aspergillosi
n
one
patient
proven
ifi
without
detect
aspergillu
time
lung
resect
median
time
day
rang
patient
still
caspofungin
prophylaxi
patient
die
cohort
univari
analysi
os
nrm
hazard
ratio
hr
patient
rel
patient
without
ifi
ci
p
ci
p
respect
analyz
risk
factor
commonli
associ
fungal
infect
univari
analysi
found
tabl
longer
neutropen
phase
higher
chanc
experienc
within
first
day
caspofungin
prophylaxi
limit
engraft
phase
ifi
occur
day
cumul
incid
perform
subanalysi
studi
whether
day
correl
gitmo
risk
categori
could
find
signific
differ
standard
risk
vs
high
risk
p
note
multivari
analysi
highveri
high
diseas
risk
index
dri
retain
independ
valu
increas
risk
ifi
hr
p
howev
confid
interv
wide
due
small
number
event
therefor
result
need
confirm
larger
number
patient
addit
compar
cumul
incid
cohort
histor
group
patient
n
receiv
iv
itraconazol
pap
april
octob
institut
two
group
differ
patient
characterist
sinc
cohort
receiv
caspofungin
older
higher
frequenc
previou
autolog
transplant
intens
condit
tabl
take
limit
consider
observ
trend
reduc
cumul
incid
caspofungin
rel
itraconazol
prophylaxi
ci
vs
ci
figur
p
patient
evalu
patient
die
engraft
experienc
graft
failur
median
time
anc
day
rang
median
time
platelet
count
rang
note
patient
neutropenia
last
day
median
aliv
patient
month
rang
patient
still
aliv
os
ci
figur
pf
ci
nrm
ci
figur
cumul
incid
grade
acut
gvhd
month
ci
figur
ci
respect
median
day
acut
gvhd
onset
day
rang
cumul
incid
chronic
gvhd
ci
figur
median
day
onset
day
rang
patient
posit
cmv
serostatu
cumul
incid
cmv
reactiv
requir
therapi
tabl
report
diagnosi
pneumon
perform
within
first
day
cohort
patient
relev
abl
perform
bronchoalveolar
lavag
case
pneumon
allow
significantli
reduc
percentag
cohort
possibl
perform
bronchoalveolar
lavag
patient
due
sever
compromis
perform
statu
detail
preval
radiolog
pattern
consist
multipl
area
consolid
without
opac
involv
either
upper
inferior
lobe
lung
suspect
treatment
choic
shift
antifung
class
caspofungin
voriconazol
ambisom
treatment
n
case
moreov
result
bal
allow
modifi
antibacteri
treatment
n
case
initi
therapi
n
case
among
case
pneumon
one
die
cmv
lung
infect
day
one
patient
experienc
lung
aspergillosi
day
die
septic
shock
day
retrospect
analysi
bring
evid
efficaci
caspofungin
primari
antifung
prophylaxi
patient
undergo
higher
risk
mold
infect
rel
mrd
counterpart
found
cumul
incid
compar
well
one
report
literatur
recipi
past
year
gradual
replac
tcd
transplant
suppos
better
immun
reconstitut
low
incid
immunolog
complic
opportunist
infect
ciurea
et
al
risk
ifi
time
higher
tcd
transplant
compar
due
delay
immun
reconstitut
beij
group
util
giac
platform
found
cumul
incid
ifi
day
year
di
bartolomeo
et
use
similar
platform
ad
basiliximab
alreadi
intensifi
immunosuppress
regimen
describ
higher
incid
ifi
earli
phase
follow
late
one
baltimor
platform
cumul
incid
vari
retrospect
studi
raiola
et
fluconazol
use
pap
recipi
experienc
aspergillu
frequent
agent
follow
candida
fusarium
speci
anoth
report
group
patient
receiv
fluconazol
minor
caspofungin
follow
itraconazol
cumul
incid
recent
experi
report
micafungin
prophylaxi
yield
cumul
incid
present
studi
compar
well
mention
report
ifi
recipi
cumul
incid
ifi
stand
lower
rang
ifi
document
use
baltimor
platform
even
possibl
compar
present
result
previou
studi
due
great
variabl
condit
regimen
diseas
type
diseas
statu
import
point
patient
die
ifi
cohort
patient
result
quiet
similar
report
raiola
et
differ
beij
experi
os
patient
ifi
vs
patient
without
whether
differ
may
due
differ
gvhd
prophylaxi
regimen
one
beij
intensifi
differ
hospit
microbiolog
flora
difficult
interpret
optim
treatment
antifung
prophylaxi
recipi
remain
uncertain
mainli
due
lack
random
clinic
trial
directli
compar
differ
drug
option
patient
recent
identif
risk
factor
ifi
follow
distinct
vs
categori
make
result
previou
random
studi
even
outdat
enough
power
detect
differ
drug
efficaci
accord
ifi
risk
recent
five
random
studi
shown
rel
fluconazol
pap
itraconazol
voriconazol
posaconazol
reduc
incid
wherea
posaconazol
voriconazol
seem
superior
oral
itraconazol
order
reduc
incid
invas
detail
cumul
incid
low
phase
studi
rang
note
studi
includ
patient
receiv
match
relat
match
unrel
donor
therefor
well
known
efficaci
voriconazol
posaconazol
set
accord
find
recent
updat
german
australian
consist
propos
fluconazol
pap
transplant
agent
choic
posaconazol
voriconazol
itraconazol
subject
high
risk
caspofungin
receiv
c
level
recommend
australian
guidelin
lack
data
last
ecil
context
studi
first
report
adult
provid
evid
efficaci
caspofungin
prevent
ifi
high
risk
mold
infect
one
recent
studi
pediatr
patient
compar
amphotericin
b
caspofungin
pap
studi
caspofungin
result
excel
protect
ifi
patient
develop
anoth
import
observ
studi
besid
similar
efficaci
two
compound
superior
safeti
profil
caspofungin
rel
consist
observ
either
kidney
liver
toxic
interact
cyclosporin
low
therefor
avoid
need
frequent
cyclosporin
dose
adjust
expect
fluconazol
data
shown
therefor
rel
avail
antifung
agent
caspofungin
provid
advantag
disadvantag
probabl
effect
fluconazol
mold
infect
less
interact
drug
expens
rel
posaconazol
voriconazol
clear
whether
provid
level
protect
mold
infect
less
expens
safer
profil
term
organ
toxic
drug
interact
risk
factor
develop
ifi
patient
receiv
well
known
sun
et
giac
platform
identifi
platelet
engraft
time
day
grade
acut
gvhd
underli
diseas
import
risk
factor
ifi
studi
found
univari
analysi
direct
correl
risk
ifi
increas
number
day
neutropenia
confirm
multivari
analysi
advanc
dri
came
variabl
affect
probabl
develop
ifi
howev
result
read
caution
due
rel
low
number
n
event
cohort
cours
retrospect
studi
affect
sever
limit
fact
patient
receiv
ric
nma
transplant
may
result
reduc
incid
note
observ
increas
incid
subgroup
receiv
mac
transplant
data
shown
moreov
restrict
analysi
first
day
transplant
may
induc
us
lose
small
part
event
decid
mani
factor
antifung
prophylaxi
acut
chronic
gvhd
known
play
predomin
role
occurr
ifi
day
moreov
recent
evid
one
gitmo
show
occur
first
day
anoth
limit
studi
concern
comparison
itraconazol
prophylaxi
unfortun
even
observ
trend
reduc
cohort
receiv
caspofungin
definit
conclus
taken
probabl
differ
characterist
group
patient
caspofungin
advers
featur
moreov
data
blood
concentr
itraconazol
avail
even
patient
receiv
iv
itraconazol
thu
reduc
risk
low
blood
level
frequent
observ
oral
formul
conclus
found
pap
caspofungin
phase
result
manag
incid
platform
larger
prospect
studi
warrant
order
identifi
agent
may
reduc
cumul
incid
provenprob
ifi
context
author
conflict
interest
disclos
